These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22126739)

  • 1. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
    Dooley KE; Park JG; Swindells S; Allen R; Haas DW; Cramer Y; Aweeka F; Wiggins I; Gupta A; Lizak P; Qasba S; van Heeswijk R; Flexner C;
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):455-62. PubMed ID: 22126739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.
    Svensson EM; Aweeka F; Park JG; Marzan F; Dooley KE; Karlsson MO
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2780-7. PubMed ID: 23571542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
    McIlleron HM; Schomaker M; Ren Y; Sinxadi P; Nuttall JJ; Gous H; Moultrie H; Eley B; Merry C; Smith P; Haas DW; Maartens G
    AIDS; 2013 Jul; 27(12):1933-40. PubMed ID: 24180002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
    Dooley KE; Luetkemeyer AF; Park JG; Allen R; Cramer Y; Murray S; Sutherland D; Aweeka F; Koletar SL; Marzan F; Bao J; Savic R; Haas DW;
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5245-52. PubMed ID: 24957823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
    Malvestutto CD; Ma Q; Morse GD; Underberg JA; Aberg JA
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):390-6. PubMed ID: 25202920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
    Rekić D; Röshammar D; Mukonzo J; Ashton M
    Br J Clin Pharmacol; 2011 Apr; 71(4):536-43. PubMed ID: 21395646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
    Gausi K; Wiesner L; Norman J; Wallis CL; Onyango-Makumbi C; Chipato T; Haas DW; Browning R; Chakhtoura N; Montepiedra G; Aaron L; McCarthy K; Bradford S; Vhembo T; Stranix-Chibanda L; Masheto GR; Violari A; Mmbaga BT; Aurpibul L; Bhosale R; Nevrekhar N; Rouzier V; Kabugho E; Mutambanengwe M; Chanaiwa V; Nyati M; Mhembere T; Tongprasert F; Hesseling A; Shin K; Zimmer B; Costello D; Jean-Philippe P; Sterling TR; Theron G; Weinberg A; Gupta A; Denti P;
    Clin Pharmacol Ther; 2021 Apr; 109(4):1034-1044. PubMed ID: 32909316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
    PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.
    Healan AM; Griffiss JM; Proskin HM; O'Riordan MA; Gray WA; Salata RA; Blumer JL
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
    Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
    Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
    Haas DW; Cramer YS; Godfrey C; Rosenkranz SL; Aweeka F; Berzins B; Coombs R; Coughlin K; Moran LE; Gingrich D; Zorrilla CD; Baker P; Cohn SE; Scarsi KK;
    Pharmacogenet Genomics; 2020 Apr; 30(3):45-53. PubMed ID: 32106141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.
    Olagunju A; Schipani A; Bolaji O; Khoo S; Owen A
    J Antimicrob Chemother; 2018 Jan; 73(1):165-172. PubMed ID: 29029267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B;
    Lancet Infect Dis; 2021 Jun; 21(6):813-822. PubMed ID: 33667406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.